Literature DB >> 15896439

Oral acute toxic class method: a successful alternative to the oral LD50 test.

Eva Schlede1, Elke Genschow, Horst Spielmann, Gisela Stropp, Detlev Kayser.   

Abstract

The oral acute toxic class method (ATC method) was developed as an alternative to replace the oral LD50 test. The ATC method is a sequential testing procedure using only three animals of one sex per step at any of the defined dose levels. Depending on the mortality rate three but never more than six animals are used per dose level. This approach results in the reduction of numbers of animals used in comparison to the LD50 test by 40-70%. The principle of the oral ATC method is based on the Probit model and it was first evaluated on a biometric basis before a national and subsequently an international ring study were conducted. The results demonstrated an excellent agreement between the toxicity and the animal numbers predicted biometrically and observed in the validation studies. The oral ATC method was adopted as an official test guideline by OECD in 1996 and was slightly amended in 2001. The ATC method has been successfully used in Germany and in 2003 >85% of all tests on acute oral toxicity testing was conducted as oral ATC tests. In member states of the European Union the ATC method is used in the range of 50% of all tests conducted. Meanwhile the oral LD50 test has been deleted by OECD, by the European Union and by the USA, making the use of alternatives to the oral LD50 test mandatory.

Entities:  

Mesh:

Year:  2005        PMID: 15896439     DOI: 10.1016/j.yrtph.2004.12.006

Source DB:  PubMed          Journal:  Regul Toxicol Pharmacol        ISSN: 0273-2300            Impact factor:   3.271


  7 in total

1.  Hepatoprotective effects of Gentianella turkestanerum extracts on acute liver injury induced by carbon tetrachloride in mice.

Authors:  Jianghua Yang; Dandan Zhu; Bowei Ju; Xiangying Jiang; Junping Hu
Journal:  Am J Transl Res       Date:  2017-02-15       Impact factor: 4.060

2.  Experimental chemotherapy against Trypanosoma cruzi infection using ruthenium nitric oxide donors.

Authors:  Jean Jerley N Silva; Wander R Pavanelli; José Clayston M Pereira; João S Silva; Douglas W Franco
Journal:  Antimicrob Agents Chemother       Date:  2009-07-06       Impact factor: 5.191

3.  Novel ruthenium complexes as potential drugs for Chagas's disease: enzyme inhibition and in vitro/in vivo trypanocidal activity.

Authors:  Jean Jerley Nogueira Silva; Paulo Marcos Matta Guedes; Aderson Zottis; Tatiane Luciano Balliano; Francisco Ordelei Nascimento Silva; Luiz Gonzaga França Lopes; Javier Ellena; Glaucius Oliva; Adriano Defini Andricopulo; Douglas Wagner Franco; João Santana Silva
Journal:  Br J Pharmacol       Date:  2010-01-26       Impact factor: 8.739

4.  Evaluation of the acute oral toxicity class of trinuclear chromium(III) glycinate complex in rat.

Authors:  Halina Staniek; Zbigniew Krejpcio; Katarzyna Iwanik; Henryk Szymusiak; Daria Wieczorek
Journal:  Biol Trace Elem Res       Date:  2011-01-18       Impact factor: 3.738

5.  In vivo efficacy of a synthetic coumarin derivative in a murine model of aspergillosis.

Authors:  Seema Singh; Rajesh Dabur; Madhumanjiri M Gatne; Bharat Singh; Shilpi Gupta; Sharad Pawar; Sunil K Sharma; Gainda L Sharma
Journal:  PLoS One       Date:  2014-08-20       Impact factor: 3.240

6.  Non-toxic doses of modified titanium dioxide nanoparticles (m-TiO2NPs) in albino CFW mice.

Authors:  Mónica Basante-Romo; Jose Oscar Gutiérrez-M; Rubén Camargo-Amado
Journal:  Heliyon       Date:  2021-03-16

7.  Efficacy and safety evaluation of a novel trioxaquine in the management of cerebral malaria in a mouse model.

Authors:  Onyango C Odhiambo; Hannah N Wamakima; Gabriel N Magoma; Peter G Kirira; Bonface J Malala; Francis T Kimani; Francis W Muregi
Journal:  Malar J       Date:  2017-07-03       Impact factor: 2.979

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.